DexCom, Inc. vs Paycom Software Inc — how do they compare? DexCom, Inc. trades at $88.98 (market cap $33.79B), while Paycom Software Inc trades at $205.13 (market cap $9.57B). The key difference: DexCom, Inc. is far larger — about 3.5× Paycom Software Inc's market cap, and Paycom Software Inc pays a 0.71% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | PAYC | |
|---|---|---|
Market Cap | $33.79B | $9.57B |
Sector | Health | Technology |
52-Week High | $89.53 | $233.89 |
52-Week Low | $54.84 | $113.59 |
Enterprise Value | $33.24B | $10.35B |
Dividend Yield | — | 0.71% |
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Paycom Software (PAYC) trades at $209.22, down 1.98% over 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings of $2.78 per share, beating estimates, and raised its full-year outlook, driven by 10% revenue growth and AI-driven demand. Fundamentals show robust profitability with a 22.78% net income margin and 41.09% ROE, though valuation multiples like P/E of 22.46 are elevated. Recent news highlights operational efficiency and dividend declarations.
The outlook remains positive given consistent earnings beats and raised guidance, but risks include high valuation and competitive pressures. Analyst consensus is mixed with a $219.22 price target, suggesting moderate upside. Investors should weigh strong fundamentals against potential overvaluation and market sentiment shifts.
Trailing returns across standard periods
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →